Curanex Pharmaceuticals Prices $15 Million Initial Public Offering

MT Newswires Live

Aug 26

Curanex Pharmaceuticals (CURX) said Tuesday it priced its initial public offering of 3.75 million common shares at $4 each, for gross proceeds of $15 million.

IPO underwriters have a 45-day overallotment option to acquire up to 562,500 additional shares.

The developmental-stage pharmaceutical company said it expects its shares to start trading on the Nasdaq Capital Market under the ticker symbol CURX Tuesday.

It expects the IPO to close Wednesday and plans to use the proceeds for the development of its lead product candidate, Phyto-N, to treat ulcerative colitis, among other things.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2562373372"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562373372\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562373372?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-26 19:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562373372","market":"fut","top_or_hot":-1,"title":"Curanex Pharmaceuticals Prices $15 Million Initial Public Offering","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CURX\">Curanex Pharmaceuticals</a> (CURX) said Tuesday it priced its initial public offering of 3.75 million common shares at $4 each, for gross proceeds of $15 million.</p><p>IPO underwriters have a 45-day overallotment option to acquire up to 562,500 additional shares.</p><p>The developmental-stage pharmaceutical company said it expects its shares to start trading on the Nasdaq Capital Market under the ticker symbol CURX Tuesday.</p><p>It expects the IPO to close Wednesday and plans to use the proceeds for the development of its lead product candidate, Phyto-N, to treat ulcerative colitis, among other things.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Curanex Pharmaceuticals Prices $15 Million Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCuranex Pharmaceuticals Prices $15 Million Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-26 19:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CURX\">Curanex Pharmaceuticals</a> (CURX) said Tuesday it priced its initial public offering of 3.75 million common shares at $4 each, for gross proceeds of $15 million.</p><p>IPO underwriters have a 45-day overallotment option to acquire up to 562,500 additional shares.</p><p>The developmental-stage pharmaceutical company said it expects its shares to start trading on the Nasdaq Capital Market under the ticker symbol CURX Tuesday.</p><p>It expects the IPO to close Wednesday and plans to use the proceeds for the development of its lead product candidate, Phyto-N, to treat ulcerative colitis, among other things.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CURX","symbol_name":"Curanex Pharmaceuticals","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2562373372","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562373372","pubTimestamp":1756209321,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Curanex Pharmaceuticals  said Tuesday it priced its initial public offering of 3.75 million common shares at $4 each, for gross proceeds of $15 million.IPO underwriters have a 45-day overallotment option to acquire up to 562,500 additional shares.The developmental-stage pharmaceutical company said it expects its shares to start trading on the Nasdaq Capital Market under the ticker symbol CURX Tuesday.It expects the IPO to close Wednesday and plans to use the proceeds for the development of its lead product candidate, Phyto-N, to treat ulcerative colitis, among other things.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CURX":"Curanex Pharmaceuticals"},"translate_title":"Curanex制药公司首次公开募股定价1500万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CURX":1},"content_text":"Curanex Pharmaceuticals (CURX) said Tuesday it priced its initial public offering of 3.75 million common shares at $4 each, for gross proceeds of $15 million.IPO underwriters have a 45-day overallotment option to acquire up to 562,500 additional shares.The developmental-stage pharmaceutical company said it expects its shares to start trading on the Nasdaq Capital Market under the ticker symbol CURX Tuesday.It expects the IPO to close Wednesday and plans to use the proceeds for the development of its lead product candidate, Phyto-N, to treat ulcerative colitis, among other things.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}